Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes. [PDF]
Front ImmunolWei Y +12 more
europepmc +1 more source
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time? [PDF]
Hematology Am Soc Hematol Educ ProgramAtluri H, Abaza Y, Altman JK.
europepmc +1 more source
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents. [PDF]
Eur J HaematolVigna E +11 more
europepmc +1 more source
Effective Non-Invasive Delivery of Epigenetic Drugs Using Functionalized Accessory Unit Conjugates. [PDF]
PharmaceuticsTashima T.
europepmc +1 more source
Meta-analysis of clinical efficacy and safety of decitabine combined with CAG regimen in the treatment of acute myeloid leukemia in the elderly. [PDF]
Leuk Res RepHe Y, Zhang L, Liu M, Zhang F, Gao H.
europepmc +1 more source
Rewriting nuclear epigenetic scripts in mitochondrial diseases as a strategy for heteroplasmy control. [PDF]
EMBO Mol MedPérez MJ +6 more
europepmc +1 more source
Related searches:
Decitabine is a hypomethylating agent. Its action in DNA leads to the reactivation of tumour suppressor genes and the subsequent differentiation of cancer cells. In a randomised, phase III trial in patients (n = 170) with myelodysplastic syndromes (MDS), intravenous decitabine (45 mg/m(2)/day for 3 consecutive days every 6 weeks) combined with ...
Kate, McKeage, Katherine F, Croom
exaly +4 more sources
The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy derivative, 5-aza-2'-deoxycytidine (decitabine, Dacogen, are the most widely used inhibitors of DNA methylation which trigger demethylation leading to a consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo.
Daskalakis, Michael +2 more
+6 more sources